P. Buchner

Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients.

R. Greil, C. Dittrich, M. Czejka, 2016, Anticancer research.

Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model

C. Dittrich, M. Czejka, A. Gruber, 2018, Cancer Chemotherapy and Pharmacology.

Validation of a simple assay for the quantification of the capecitabine metabolites 5'-DFCR and 5'-DFUR for drug monitoring in patients receiving outpatient chemotherapy.

C. Dittrich, M. Czejka, P. Buchner, 2013, Anticancer research.

Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial

M. Mittlböck, C. Dittrich, M. Czejka, 2018, Investigational new drugs.

Evidence for the Conversion of Docetaxel into 7-Epidocetaxel in Patients Receiving Conventional Taxotere® Based Chemotherapy

R. Greil, M. Czejka, J. Schierholz, 2014 .

Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels

C. Dittrich, M. Czejka, P. Buchner, 2013, Case Reports in Oncology.

A Simple Method for Comparing Enzymatic Capecitabine Activation in Various Mono- and Combination Chemotherapies

C. Dittrich, M. Czejka, P. Buchner, 2015, Pharmacology.

Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.

W. Scheithauer, A. Farkouh, J. Schueller, 2014, Anticancer research.